经导管三尖瓣置换术治疗重度三尖瓣反流患者
这项同情性多中心研究纳入46例不适合手术的重度三尖瓣反流患者,在全身麻醉下经微创开胸及经心房途径行经导管三尖瓣置换术。手术成功率为97.8%,6个月死亡率为17.4%,6个月时三尖瓣反流显著减轻且主要安全终点达标38例(82.6%)。
要点
- 经导管三尖瓣置换术在高危重度三尖瓣反流患者中可行,手术成功率97.8%。
- 6个月随访三尖瓣反流显著减轻,主要安全终点达标率82.6%。
- 6个月死亡率17.4%,随访中器械移位发生1例(2.4%)。
核心结论
- 经导管三尖瓣置换术在重度三尖瓣反流患者中可行、安全且并发症发生率低。
研究设计与样本
- 同情性多中心研究,2018年9月至2019年11月纳入46例不适合手术的三尖瓣反流患者,在全身麻醉及经食管超声和透视引导下经微创开胸及经心房途径行经导管三尖瓣置换术。
主要发现
- 全部患者均为重度三尖瓣反流,缩流颈宽度为12.6(11.0,14.5)mm。
- 手术成功率为97.8%,仅1例因右心室穿孔未成功。
- 手术时间为150.0(118.8,180.0)min,重症监护时间为2.0(1.0,4.0)天。
- 6个月死亡率为17.4%,随访中器械移位发生1例(2.4%)。
- 术后6个月经胸超声心动图显示三尖瓣反流显著减轻(无/微量33例、轻度4例、中度1例),主要安全终点达标38例(82.6%)。
关键数值与推荐
- 术后6个月外周水肿从基线100.0%降至2.6%,腹水从基线47.8%降至0.0%。
临床怎么用
- 对于不适合外科手术的重度三尖瓣反流高危患者,经导管三尖瓣置换术可作为可行的介入治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tricuspid regurgitation (TR) is a common valvular heart disease with unsatisfactory medical therapeutics and high surgical mortality. The present study aims to evaluate the safety and effectiveness of transcatheter tricuspid valve replacement (TTVR) in high-risk patients with severe TR. METHODS: This was a compassionate multicentre study. Between September 2018 and November 2019, 46 patients with TR who were not suitable for surgery received compassionate TTVR under general anaesthesia and the guidance of trans-oesophageal echocardiography and fluoroscopy in four institutions. Access to the tricuspid valve was obtained via a minimally invasive thoracotomy and transatrial approach. Patients' data at baseline, before discharge, 30 days and 6 months after the procedure were collected. RESULTS: All patients had severe TR with vena contracta width of 12.6 (11.0, 14.5) mm. Procedural success (97.8%) was achieved in all but one case with right ventricle perforation. The procedural time was 150.0 (118.8, 180.0) min. Intensive care unit time was 2.0 (1.0, 4.0) days. 6-month mortality was 17.4%. Device migration occurred in one patient (2.4%) during follow-up. Transthoracic echocardiography at 6 months after operation showed TR was significantly reduced (none/trivial in 33, mild in 4 and moderate in 1) and the primary safety end point was achieved in 38 cases (82.6%). Patients suffered from peripheral oedema and ascites decreased from 100.0% and 47.8% at baseline to 2.6% and 0.0% at 6 months. CONCLUSIONS: The present study showed TTVR was feasible, safe and with low complication rates in patients with severe TR.
引用
- Lu FL, An Z, Ma Y, et al. Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Heart. 2021. PMID: 33419880. doi:10.1136/heartjnl-2020-318199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。